Last reviewed · How we verify
GSK Malaria vaccine 257049
GSK Malaria vaccine 257049 is a Subunit vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Malaria prevention.
Induces immune response against Plasmodium falciparum
Induces immune response against Plasmodium falciparum Used for Malaria prevention.
At a glance
| Generic name | GSK Malaria vaccine 257049 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Subunit vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The vaccine works by stimulating the body's immune system to produce antibodies against the malaria parasite, providing protection against infection.
Approved indications
- Malaria prevention
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique. (PHASE1)
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa (PHASE3)
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa (PHASE3)
- Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (PHASE3)
- Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults (PHASE2)
- Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults (PHASE2)
- Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Malaria vaccine 257049 CI brief — competitive landscape report
- GSK Malaria vaccine 257049 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Malaria vaccine 257049
What is GSK Malaria vaccine 257049?
How does GSK Malaria vaccine 257049 work?
What is GSK Malaria vaccine 257049 used for?
Who makes GSK Malaria vaccine 257049?
What drug class is GSK Malaria vaccine 257049 in?
What development phase is GSK Malaria vaccine 257049 in?
What are the side effects of GSK Malaria vaccine 257049?
Related
- Drug class: All Subunit vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Malaria prevention
- Compare: GSK Malaria vaccine 257049 vs similar drugs
- Pricing: GSK Malaria vaccine 257049 cost, discount & access